RxDoctor Payments Data

Laurie Bruening

Family · Chardon, OHNPI 1457996043

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AbbVie at 28.5% of the total. 2025 is the largest year on record at $120, 4.2 times the $29 reported in 2021. That places this record below the midpoint for family clinicians in OH, where the typical reported total is $331.

$319in general payments, 2019–2025

Across 17 payments — averaging $18.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$91
  • Otsuka America Pharmaceutical, Inc.$50
  • Bayer$36
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$29
  • Alkermes, Inc.$24
  • Hologic Sales And Service, LLC$23
  • plus $66 from 4 others

What the payments were for

  • Food & beverage$319100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$319 in reported general payments places this provider in the 45th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio →

Medicare billing

Part B allowed, 2024
$15,584
Medicare patients
90
Services billed
159

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin25$31,679
Gabapentin58$2,322
Levothyroxine Sodium225$1,576
Atorvastatin Calcium164$1,434
Albuterol Sulfate HfaAlbuterol Sulfate51$1,408
SynthroidLevothyroxine Sodium16$1,326
Omeprazole79$1,204
Losartan Potassium124$1,025
Pantoprazole Sodium51$986
Rosuvastatin Calcium77$921
Metoprolol Succinate76$880
Amlodipine Besylate116$722
ClopidogrelClopidogrel Bisulfate34$680
Lisinopril102$637
Escitalopram Oxalate44$630

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$14$31,67925 claims
AbbVieSynthroid$91$1,32616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 6,812 family providers in Ohio.

Other family in Chardon

See the full list for Ohio →

Where these figures come from

Is this you, or does something look wrong? →